The Global Gastrointestinal Partnering 2010-2016: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the gastrointestinal partnering deals and agreements entered into by the worlds leading healthcare companies Global Gastrointestinal Partnering 2010 to 2016 provides the full collection of Gastrointestinal disease deals signed between the worlds pharmaceutical and biotechnology companies since 2010.
Trends in Gastrointestinal partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Gastrointestinal partnering agreement structure
Gastrointestinal partnering contract documents
Top Gastrointestinal deals by value
Most active Gastrointestinal dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensors product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.
The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Gastrointestinal dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Gastrointestinal dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Gastrointestinal deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Gastrointestinal deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2010. The chapter is organized by specific Gastrointestinal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Gastrointestinal partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gastrointestinal technologies and products.
Global Gastrointestinal Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Gastrointestinal trends and structure of deals entered into by leading companies worldwide.
Global Gastrointestinal Partnering 2010 to 2016 includes:
Trends in Gastrointestinal dealmaking in the biopharma industry since 2010
Analysis of Gastrointestinal deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Gastrointestinal deal contract documents
Comprehensive access to over 3500 Gastrointestinal deal records
The leading Gastrointestinal deals by value since 2010
Most active Gastrointestinal dealmakers since 2010
The report includes deals for the following indications: Appendicitis, Celiac disease, Esophageal reflux, Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohns disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation, Diarrhea, Jaundice, Vomitting, plus other gastrointestinal indications.
In Global Gastrointestinal Partnering 2010 to 2016, available deals and contracts are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Gastrointestinal Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 400 gastrointestinal deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Chapter 1 Introduction
Chapter 2 Trends in Genetic Disorders dealmaking
2.2. Genetic Disorders partnering over the years
2.3. Genetic Disorders partnering by deal type
2.4. Genetic Disorders partnering by industry sector
2.5. Genetic Disorders partnering by stage of development
2.6. Genetic Disorders partnering by technology type
2.7. Genetic Disorders partnering by therapeutic indication
Chapter 3 Financial deal terms for Genetic Disorders partnering
3.2. Disclosed financials terms for Genetic Disorders partnering
3.3. Genetic Disorders partnering headline values
3.4. Genetic Disorders deal upfront payments
3.5. Genetic Disorders deal milestone payments
3.6. Genetic Disorders royalty rates
Chapter 4 Leading Genetic Disorders deals and dealmakers
4.2. Most active in Genetic Disorders partnering
4.3. List of most active dealmakers in Genetic Disorders
4.4. Top Genetic Disorders deals by value
Chapter 5 Genetic Disorders contract document directory
5.2. Genetic Disorders partnering deals where contract document available
Chapter 6 Genetic Disorders dealmaking by therapeutic target
6.2. Deals by Genetic Disorders therapeutic target
Appendix 1 Directory of Genetic Disorders deals by company A-Z 2010 to 2016
Appendix 2 Directory of Genetic Disorders deals by deal type 2010 to 2016
Appendix 3 Directory of Genetic Disorders deals by stage of development 2010 to 2016
Appendix 4 Directory of Genetic Disorders deals by technology type 2010 to 2016
List Of Figures
Figure 1: Genetic Disorders partnering since 2010
Figure 2: Genetic Disorders partnering by deal type since 2010
Figure 3: Genetic Disorders partnering by industry sector since 2010
Figure 4: Genetic Disorders partnering by stage of development since 2010
Figure 5: Genetic Disorders partnering by technology type since 2010
Figure 6: Genetic Disorders partnering by indication since 2010
Figure 7: Genetic Disorders deals with a headline value
Figure 8: Genetic Disorders deals with upfront payment values
Figure 9: Genetic Disorders deals with milestone payment
Figure 10: Genetic Disorders deals with royalty rates
Figure 11: Active Genetic Disorders dealmaking activity 2010 to 2016
Figure 12: Top Genetic Disorders deals by value since 2010
Notes:Sales, means the sales volume of Worktops and Window SillsRevenue, means the sales value of Worktops and Window SillsThis report studies sales (consumption) of Worktops and Window Sills in Global
Notes:Sales, means the sales volume of WorktopsRevenue, means the sales value of WorktopsThis report studies sales (consumption) of Worktops in Global market, especially in United States, China, Europe and Japan,
Notes:Sales, means the sales volume of Wood Based PanelsRevenue, means the sales value of Wood Based PanelsThis report studies sales (consumption) of Wood Based Panels in Global market, especially in
Notes:Sales, means the sales volume of Genetically Modified SeedsRevenue, means the sales value of Genetically Modified SeedsThis report studies sales (consumption) of Genetically Modified Seeds in Global market, especially in
Global Genetic Disorders Partnering 2010 to 2017 provides the full collection of Genetic Disorders disease deals signed between the worlds pharmaceutical and biotechnology companies since 2010. Trends in Genetic Disorders
Notes:Production, means the output of Genetic Engineering DrugRevenue, means the sales value of Genetic Engineering DrugThis report studies Genetic Engineering Drug in Global market, especially in North America, Europe, China,
If you want to purchase particular section from this report then kindly contact us at firstname.lastname@example.org.